# Pfizer (NSE: PFIZER) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/PFIZER · Pivot · prices to 22 Oct 2026

Pfizer (NSE: PFIZER) closed at ₹3,712.10 on 22 Oct 2026, down 0.93% on the day. With a market capitalisation of ₹16,982 Cr, it ranks 387th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - General.

At its last close the stock traded at 23.5× trailing earnings, against a return on equity of 33.2% in FY09. Over the past year the share price has fallen 30.9%. Its 52-week range is ₹3,681.50 (22 Oct 2026) to ₹5,446.00 (23 Oct 2025); the last close is 31.8% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹653 Cr (+8.3% year on year) and net profit ₹204 Cr (+6.6%), on a standalone basis. Promoters held 63.92% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹3,712.10 |
| Market cap | ₹16,982 Cr |
| P/E (trailing) | 23.5 |
| ROE | 33.2% (FY09) |
| ROCE | 33.1% (FY09) |
| Debt to equity | 0 |
| 52-week high | ₹5,446.00 (23 Oct 2025) |
| 52-week low | ₹3,681.50 (22 Oct 2026) |
| 1-year return | −30.9% |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹653 Cr | +8.3% | ₹204 Cr | +6.6% | ₹44.69 |
| Q4 FY26 | ₹629 Cr | +6.3% | ₹200 Cr | −39.6% | ₹43.68 |
| Q3 FY26 | ₹645 Cr | +19.9% | ₹142 Cr | +11.2% | ₹31.01 |
| Q2 FY26 | ₹642 Cr | +9.1% | ₹189 Cr | +19.4% | ₹41.32 |
| Q1 FY26 | ₹603 Cr | +7.1% | ₹192 Cr | +27.2% | ₹41.91 |
| Q4 FY25 | ₹592 Cr | +8.3% | ₹331 Cr | +85.0% | ₹72.34 |
| Q3 FY25 | ₹538 Cr | −0.4% | ₹128 Cr | −1.8% | ₹27.89 |
| Q2 FY25 | ₹589 Cr | +2.3% | ₹158 Cr | +6.3% | ₹34.61 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY09 | ₹733 Cr | ₹300 Cr |
| FY08 | ₹736 Cr | ₹340 Cr |
| FY07 | ₹734 Cr | ₹106 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 63.92%
- Foreign institutions: 1.65%
- Domestic institutions: 17.80%
- Non-institutions: 16.63%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Cohance Lifesciences](https://app.pivotnow.in/stock/COHANCE) | ₹460.30 | ₹17,610 Cr | 98.6 | — |
| [Shilpa Medicare](https://app.pivotnow.in/stock/SHILPAMED) | ₹880.90 | ₹17,229 Cr | 70.9 | — |
| [Caplin Point Laboratories](https://app.pivotnow.in/stock/CAPLIPOINT) | ₹2,227.80 | ₹16,934 Cr | — | — |
| [Eris Lifesciences](https://app.pivotnow.in/stock/ERIS) | ₹1,143.60 | ₹15,848 Cr | 25.3 | — |
| [Onesource Specialty Pharma](https://app.pivotnow.in/stock/ONESOURCE) | ₹1,378.00 | ₹15,798 Cr | — | — |
| [Alivus Life Sciences](https://app.pivotnow.in/stock/ALIVUS) | ₹1,272.00 | ₹15,612 Cr | 27.7 | — |

## Questions and answers

### What is the share price of Pfizer today?

Pfizer (NSE: PFIZER) last closed at ₹3,712.10 on 22 Oct 2026. Its 52-week high is ₹5,446.00 and its 52-week low is ₹3,681.50.

### What is the market cap of Pfizer?

Pfizer's market capitalisation is ₹16,982 Cr (₹16,982 Cr) at the 22 Oct 2026 close, ranking 387th among the NSE companies Pivot tracks.

### What is the P/E ratio of Pfizer?

Pfizer trades at a trailing P/E of 23.5. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 70.9.

### What is the ROE and ROCE of Pfizer?

Return on equity was 33.2% in FY09 and return on capital employed was 33.1% in FY09 (consolidated figures).

### Is Pfizer a debt-free company?

Pfizer is close to debt-free: its debt-to-equity ratio was 0 in FY09.

### What were Pfizer's latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Pfizer reported revenue of ₹653 Cr, +8.3% year on year, and net profit of ₹204 Cr, +6.6% year on year.

### How has Pfizer stock performed over the last year?

Pfizer's share price has fallen 30.9% over the past year, −20.2% over three months and −8.0% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Pfizer?

As of 30 Jun 2026: promoters 63.92%, foreign institutions 1.65%, domestic institutions 17.80%, non-institutions 16.63%.

### Who are Pfizer's competitors?

The listed Pharma & Healthcare companies closest to Pfizer by market cap are Cohance Lifesciences, Shilpa Medicare, Caplin Point Laboratories, Eris Lifesciences, Onesource Specialty Pharma and Alivus Life Sciences.

### Is Pfizer a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Pfizer's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on PFIZER against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.